March 28, 2025 03:51 PM EDTUpdated 04:36 PM
Deals
R&D

Blue­bird gets new M&A bid, seek­ing to top pri­vate eq­ui­ty of­fer

Max Bayer

Pharma Reporter

Drew Armstrong

Executive Editor

A ri­val group is seek­ing to buy cell ther­a­py biotech blue­bird bio, in an ef­fort to out­bid a pri­vate eq­ui­ty of­fer by Car­lyle and SK …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

TRENDING NOW

FDA's Pe­ter Marks re­signs, say­ing he won't ac­cept Kennedy's 'mis­in­for­ma­tion and lies'

BioN­Tech de­tails promis­ing mid-stage da­ta for its PD-L1xVEGF in ag­gres­sive lung can­cer

Ex­clu­sive: SV Health de­buts Parkin­son's biotech with back­ing from Ab­b­Vie and oth­ers

‘Peo­ple will die’: End of NIH grants guts work be­tween aca­d­e­mics and com­pa­nies to counter next pan­dem­ic

Eu­ro­pean reg­u­la­tor re­jects Lil­ly's Alzheimer’s drug over po­ten­tial­ly fa­tal side ef­fects

Ver­tex’s sec­ond-gen­er­a­tion di­a­betes cell ther­a­py fails ear­ly-stage study

A service from the Financial Times